MASS SPECTROMETRY OF ANTIGENIC LIPOPEPTIDES: HIV

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 从一家商业公司获得了一种脂肽的合成版本，它是最早出现在艾滋病毒感染细胞中的化合物之一，并使用来自艾滋病毒患者捐赠者的细胞来生成T细胞系。进一步分析发现，合成的靶向脂肽不是纯的，而是一种混合物，而且靶向脂肽不是抗原性的，而是发现了两个新的抗原性成分。质谱学研究表明，新的抗原组分在结构上彼此非常相似，并且具有与预期合成结构相似的结构。BUSM MS资源的质谱学研究包括使用GC/MS、MALDI和ESI Q-o-TOF和MALDI和ESI-FTMS仪器，以及已知和未知化合物的酶消化和化学水解。结构现在已经解决，合成的类似物正在准备中。这篇手稿已被《实验医学杂志》接受发表。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. A synthetic version of a lipopeptide that is one of the first compounds to appear in HIV-infected cells was obtained from a commercial company and employed to generate a T cell line, using cells from an HIV patient donor. On further analysis it was found that the synthetically produced version of the targeted lipopeptide was not pure, but in fact a mixture, and further, the targeted lipopeptide was not antigenic, but instead two novel components were found to be antigenic. Mass spectrometric investigations indicate that the new antigenic components are very similar in structure to each other and have structures similar to the intended synthetic structure. Mass spectrometric studies at the BUSM MS Resource included the use of GC/MS, MALDI and ESI Q-o-TOF and MALDI and ESI-FTMS instrumentation, enzymatic digestion and chemical hydrolysis of the known and unknown compounds. The structure has now been solved and a synthetic analogs are being prepared. The manuscript has been accepted for publication in the Journal of Experimental Medicine.